Publications

Add filters (0)

386 results

Diagnostic value of extracellular matrix degradation biomarkers in serum from patients with Parkinson’s disease.

January 15, 2025

J Neurol Sci

Abstract Parkinson’s Disease (PD) is a progressive neurodegenerative condition, which is highly heterogeneous upon diagnosis. Brain extracellular matrix (ECM) accounts for 10-20 % of the total brain volume and is responsible for the physical organization of neuronal and glia cells. Blood-based biomarkers quantifying ECM fragments holds the potential as diagnostic and prognostic biomarkers. Here we evaluated […]

Read publication

Longitudinal stability of molecular endotypes of knee osteoarthritis patients.

January 1, 2025

Osteoarthritis Cartilage

Abstract OBJECTIVE To assess the longitudinal stability of biomarker-based molecular endotypes of knee osteoarthritis (KOA) participants from APPROACH and to evaluate the consistency of findings in an independent KOA population. METHODS Nineteen biomarkers were measured longitudinally in 295 KOA participants from the APPROACH cohort. K-means clustering was used to identify the structural damage, inflammation, and […]

Read publication

Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapy.

January 1, 2025

Front Endocrinol (Lausanne)

Abstract INTRODUCTION Decline in kidney function due to renal fibrosis is a potential side effect in patients with neuroendocrine neoplasm (NEN) undergoing Peptide Receptor Radionuclide Therapy (PRRT). We aimed to investigate the potential of circulating fibrosis markers reflecting formation and degradation of collagens in predicting decline in kidney function in NEN-patients undergoing PRRT. MATERIAL AND […]

Read publication

Biomarkers of Extracellular Matrix Fragments in Patients with Psoriasis.

December 30, 2024

Int J Mol Sci

Abstract Blood-based extracellular matrix (ECM) fragments have been identified as potential pharmacologic biomarkers in spondyloarthritis and diagnostic biomarkers in psoriatic arthritis and psoriasis vulgaris. This study aimed to explore whether ECM fragments can differentiate patients with psoriasis from healthy controls (HC) and determine their potential as biomarkers for response to treatment in psoriasis. The study […]

Read publication

Plasma collagen neoepitopes are associated with multiorgan disease in the ACCESS and GRADS sarcoidosis cohorts.

November 14, 2024

Thorax

Abstract INTRODUCTION The pathogenesis of sarcoidosis involves tissue remodelling mediated by the accumulation of abnormal extracellular matrix, which is partly the result of an imbalance in collagen synthesis, cross-linking and degradation. During this process, collagen fragments or neoepitopes, are released into the circulation. The significance of these circulating collagen neoepitopes in sarcoidosis remains unknown. METHODS […]

Read publication

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

September 1, 2024

Diabetes Obes Metab

Abstract AIM To investigate type III collagen (COL III) turnover in participants from the CANVAS Program biomarker substudy. METHODS Biomarkers of COL III formation (PRO-C3) and COL III degradation fragments (C3M and CTX-III) were assessed in baseline and year 3 plasma from patients enrolled in CANVAS, investigating the effect of canagliflozin in participants with type […]

Read publication

The fibroblast hormone Endotrophin is a biomarker of mortality in chronic diseases.

September 1, 2024

Matrix Biol

Abstract Fibrosis, driven by fibroblast activities, is an important contributor to morbidity and mortality in most chronic diseases. Endotrophin, a signaling molecule derived from processing of type VI collagen by highly activated fibroblasts, is involved in fibrotic tissue remodeling. Circulating levels of endotrophin have been associated with an increased risk of mortality in multiple chronic […]

Read publication

Cluster analysis of blood biomarkers to identify molecular patterns in pulmonary fibrosis: assessment of a multicentre, prospective, observational cohort with independent validation.

September 1, 2024

Lancet Respir Med

Abstract BACKGROUND Pulmonary fibrosis results from alveolar injury, leading to extracellular matrix remodelling and impaired lung function. This study aimed to classify patients with pulmonary fibrosis according to blood biomarkers to differentiate distinct disease patterns, known as endotypes. METHODS In this cluster analysis, we first classified patients from the PROFILE study, a multicentre, prospective, observational […]

Read publication

Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases.

August 1, 2024

J Hepatol

Abstract The rising prevalence of liver diseases related to obesity and excessive use of alcohol is fuelling an increasing demand for accurate biomarkers aimed at community screening, diagnosis of steatohepatitis and significant fibrosis, monitoring, prognostication and prediction of treatment efficacy. Breakthroughs in omics methodologies and the power of bioinformatics have created an excellent opportunity to […]

Read publication

Performance of novel collagen turnover biomarkers to detect increased liver stiffness in MASLD.

August 1, 2024

J Intern Med

Abstract BACKGROUND Cleavage products from collagen formation and degradation hold potential as first-line biomarkers for the risk of advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we evaluated the performance of PRO-C3, PRO-C6, C4M, PRO-C18L, and the clinical score ADAPT (age, diabetes, PRO-C3, and platelet count) to detect patients with an […]

Read publication